|NASDAQ: APEN||Healthcare / Medical Devices & Instruments / USA|
|9.91||+0.0100||+0.10%||Vol 452.80K||1Y Perf 60.19%|
|Mar 24th, 2023 16:00 DELAYED|
|- -||-0.01 -0.10%|
|Target Price||11.00||Analyst Rating||Hold 3.00|
|Potential %||11.00||Finscreener Ranking||+ 38.88|
|Insiders Trans % 3/6/12 mo.||-/100/40||Value Ranking||★ 41.54|
|Insiders Value % 3/6/12 mo.||-/100/84||Growth Ranking||+ 29.63|
|Insiders Shares Cnt. % 3/6/12 mo.||-/100/84||Income Ranking||— -|
|Price Range Ratio 52W %||94.27||Earnings Rating||Neutral|
|Market Cap||471.21M||Earnings Date||28th Mar 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||28th Mar 2023|
|Estimated EPS Next Report||-0.21|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||704.47K|
|Avg. Monthly Volume||1.12M|
|Avg. Quarterly Volume||1.40M|
Apollo Endosurgery Inc. (NASDAQ: APEN) stock closed at 9.91 per share at the end of the most recent trading day (a 0.1% change compared to the prior day closing price) with a volume of 452.80K shares and market capitalization of 471.21M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 217 people. Apollo Endosurgery Inc. CEO is K. Todd Newton.
The one-year performance of Apollo Endosurgery Inc. stock is 60.19%, while year-to-date (YTD) performance is -0.6%. APEN stock has a five-year performance of 49.47%. Its 52-week range is between 3.49 and 10.3, which gives APEN stock a 52-week price range ratio of 94.27%
Apollo Endosurgery Inc. currently has a PE ratio of -9.40, a price-to-book (PB) ratio of 9.74, a price-to-sale (PS) ratio of 7.41, a price to cashflow ratio of 6.00, a PEG ratio of 2.32, a ROA of -46.18%, a ROC of -47.26% and a ROE of -192.68%. The company’s profit margin is -54.53%, its EBITDA margin is -41.10%, and its revenue ttm is $55.54 Million , which makes it $1.33 revenue per share.
Of the last four earnings reports from Apollo Endosurgery Inc., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.21 for the next earnings report. Apollo Endosurgery Inc.’s next earnings report date is 28th Mar 2023.
The consensus rating of Wall Street analysts for Apollo Endosurgery Inc. is Hold (3), with a target price of $11, which is +11.00% compared to the current price. The earnings rating for Apollo Endosurgery Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Apollo Endosurgery Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Apollo Endosurgery Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 33.15, ATR14 : 0.04, CCI20 : -60.61, Chaikin Money Flow : -0.04, MACD : 0.00, Money Flow Index : 37.87, ROC : -0.20, RSI : 50.86, STOCH (14,3) : 54.55, STOCH RSI : 0.50, UO : 57.96, Williams %R : -45.45), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Apollo Endosurgery Inc. in the last 12-months were:
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Hold||Hold||Moderate Buy|
Apollo Endosurgery Inc is active in the healthcare sector based in the United States. As a developer of medical devices, Apollo focusses on addressing obesity, as well as other gastrointestinal disorders. Its products are used by general surgeons, bariatric surgeons and gastroenterologists in a variety of settings to provide interventional therapy to patients who suffer from obesity. The company's products include ORBERA, LAP-BAND and OverStitch.
CEO: K. Todd Newton
Telephone: +1 512 279-5100
Address: 1120 S. Capital of Texas Highway, Austin 78746, TX, US
Number of employees: 217
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.